Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Huiqiang Huang
- Target Recruit Count
- 33
- Registration Number
- NCT04476459
- Locations
- 🇨🇳
Department of Medical Oncology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT04459078
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT04454905
- Locations
- 🇨🇳
Li Xu, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04453930
- Locations
- 🇨🇳
Beijing Union Medical College Hospital, Beijing, China
Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-06-11
- Target Recruit Count
- 59
- Registration Number
- NCT04425135
The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT04415385
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 21
- Registration Number
- NCT04393506
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital, Shanghai, Shanghai, China
Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT04383977
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT04335006
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC
- Conditions
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-04-12
- Target Recruit Count
- 46
- Registration Number
- NCT04303741
- Locations
- 🇨🇳
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Changhai Hospital, Navy Medical University (Second Military Medical University), Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.